Pathways involving TRK activity, RAS/MAPK signaling, and ERK/MAPK targets remained upregulated in the striatum after amphetamine treatment in the one ADHD model for which this data was available. This evidence concerns the gene NTRK1 and attention deficit-hyperactivity disorder.